Navigation Links
Chemo may not assist in fighting cancer

According to a study, for post-menopausal women with breast cancer that is affected by estrogen, chemotherapy may offer no benefit and a five-year course after surgery of tamoxifen, which obstructs the hormone, may be the only therapy needed. This finding could mean that some of the thousands of American women// diagnosed each year with breast cancer could avoid the debilitating side effects of taking drugs that chemically kill cancer cells and damage other cells in the body.

The study also found that for post-menopausal women whose breast cancer was not affected by estrogen, chemotherapy followed by tamoxifen offered the best hope of disease-free survival. Tamoxifen works by blocking the action of estrogen, a hormone that can promote the growth of cancer cells.

Richard D. Gelber, a biostatistician at the Dana-Farber Cancer Institute in Boston hopes that, this study will question the routine use of chemotherapy in the ER-positive (estrogen sensitive) group. The information should help physicians tailor cancer treatment for specific patients.

Dr. Andrew D. Seidman, a breast cancer specialist at Memorial Sloan-Kettering Cancer Center in New York City, said the study ``will reaffirm the way that many oncologists are now practicing'' and should help doctors base cancer therapies on the specific characteristics of their patients.

It shows chemotherapy is appropriate for some women, but not others, and that patients who need the therapy can be specifically identified based on the estrogen sensitivity of their tumors and on other factors, Seidman said.

The study, compiled by researchers from nine countries, was limited to breast cancer surgery patients who had completed menopause and whose disease had not spread to the lymph nodes. About 40 percent of the approximately 162,000 women in the United States diagnosed with breast cancer each year fit this category, the study said.

Researchers further divided the 1,550 patients in the study into groups based on whether their cancers were affected or not affected by estrogen. There were 350 in the study whose tumors were not affected by estrogen, described in medical terms as being estrogen receptor negative, or ER-negative. There were 1,000 who were ER-positive. For the remaining 75 patients, the ER status was unknown.

About half in each of these groups were treated with chemotherapy followed by five years of tamoxifen. The other half of each group received tamoxifen only. Researchers followed the patients for an average of almost six years and found the value of chemotherapy depended directly on the estrogen sensitivity of the patients' disease.

Among the ER-positive patients, chemotherapy provided no benefit. The five-year, disease-free survival rate for those who only took tamoxifen was 80 percent, while it was 84 percent for those who had both chemo and tamoxifen.

However, for the ER-negative patients, chemotherapy could be a life saver. The five-year, disease-free survival rate for those who had both chemo and tamoxifen was 82 percent. For ER-negative patients who took only tamoxifen, the survival rate was only 60 percent.

Gelber said the study may improve the lives of patients who are ER-positive because it will ensure they don't have to endure chemotherapy's side effects, such as hair loss, nausea and persistent tiredness. Gelber felt that there is a quality of life burden associated with chemotherapy. On the other hand, he said, the study showed that chemo's side effects were not severe enough that the therapy should be avoided by the ER-negative patients who would benefit. Gelber said a quality-of-life segment of the study showed the side effects from chemo are usually temporary and go away after the therapy ends.


'"/>




Related medicine news :

1. Acupuncture May Help Chemotherapy Side Effects
2. Chemotherapy Pill Has Fewer Side Effects Than IV
3. Survival rates in breast cancer patients improved with "Dose Dense Chemotherapy"
4. Therapy Boosts Chemotherapy Effects
5. Chemotherapy Effective for Bladder Cancer
6. Hope for Chemo-Resistant Leukemia Patients
7. New Method Of Delivering Chemotherapy
8. Drug That Is Found To Reduce Heart Damage from Chemo
9. The Benefits Of Chemotherapy For Women With Ovarian Cancer
10. New Compound Could Strengthen The Effect Of Chemotherapy
11. Older Breast Cancer Patients Can Be Effectively Treated With Chemotherapy
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:5/26/2017)... ... May 26, 2017 , ... ... CareFusion NOX-T3 portable sleep monitor with its Somnoware Sleep Device Interface (SDI). Somnoware ... for diagnostic device operations. With this platform, initializing devices and importing studies are ...
(Date:5/26/2017)... Sparks, Nevada (PRWEB) , ... May 26, 2017 ... ... to produce the first ever copper, antimicrobial, mesh back 24/7 task chair specifically ... and conference applications. “We are thrilled to partner with Cupron® to provide ...
(Date:5/26/2017)... Texas (PRWEB) , ... May 26, 2017 , ... Yisrayl ... a new publication this week that is focusing on the Peace Agreements being discussed ... his Middle East sprint in a race to try to speed up peace talks ...
(Date:5/26/2017)... Francisco, CA (PRWEB) , ... May 26, 2017 , ... ... Francisco, is proud to announce a new, informational blog post on insurance options. If ... surgery, checking insurance plans may help save time and money. Visiting an in-network provider ...
(Date:5/26/2017)... ... 26, 2017 , ... Centennial-based BluSky Restoration Contractors announced that ... Annual Clays for Kids fundraiser, to be held Friday, Sept. 22, at Kiowa ... part of BluSky’s partnership with The Adoption Exchange, BluSky will also share sponsorship ...
Breaking Medicine News(10 mins):
(Date:5/18/2017)...  Two Bayer U.S. Pharmaceutical leaders received top awards ... 28 th Woman of the Year ... longstanding mission of furthering the advancement and impact of ... Cindy Powell-Steffen , senior director of brand activation and ... Libby Howe , a regional business manager for New ...
(Date:5/15/2017)... Inc., a privately-held CNS pharmaceutical company based in ... disease (PD), has enrolled the first patient in the RASMET ... study involving patients with PD and taking place at 12 ... period. The first stage is open label and involves single ... Denver , Boca Raton ...
(Date:5/10/2017)... Inc. (Nasdaq: HOLX ) announced today the ... April 1, 2017 .   GAAP diluted earnings per ... prior year period as the sale of the blood ... diluted EPS of $0.50 increased 6.4%.  Revenue of $715.4 ... Excluding the effects of blood screening and the acquired ...
Breaking Medicine Technology: